AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03382353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational training
Description: 16 educational lessons (twice a week): basic principles of different cognitive domains (e.g. memory, attention, perception) and educational DVD viewing.
Study NCT03382353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling on a brain-healthy diet
Description: 4 lessons on the principles of Mediterranean Diet lead by a nutritionist, aimed to teach how to include brain-healthy foods in daily diet (e.g. antioxidant, omega-3 fatty acids and vitamins). Each participant will receive the educational material presented.
Study NCT03382353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise training
Description: 80 sessions of physical exercise supervised by a Fitness Training Expert with the aim of achieving 150 minutes of moderate-intensity physical activity per week
Study NCT03382353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: 16 cognitive training sessions (twice a week) supervised by a psychologist, aimed to improve Attention, Processing speed, Memory, Social skills and Intelligence using BrainHQ (www.brainhq.com).
Study NCT00048074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 2mg iv every 2 months
Study NCT00048074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 2.5mg po daily
Study NCT00048074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3mg iv every 3 months
Study NCT01732289 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genes
Description: Draw blood for genetic screening
Study NCT02640287 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood or bone marrow samples
Study NCT02640287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood or bone marrow samples
Study NCT02629900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
Study NCT02124785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: At Years 21 to 25 after their second vaccine dose.
Study NCT00770172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT01239693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IFA
Description: Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
Study NCT01239693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MMN
Description: Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
Study NCT01239693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS
Description: Women during pregnancy: 1 sachet of LNS-P\&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P\&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
Study NCT02991040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revanesse Ultra+ (with lidocaine)
Description: Bilateral nasolabial fold trial to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine) to Revanesse® Ultra (comparator)
Study NCT02991040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revanesse Ultra
Description: Comparator without lidocaine
Study NCT02129127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Coated Chocolate Balloon Angioplasty
Description: Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
Study NCT00575731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight management strategies
Study NCT00575731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight management strategies
Study NCT03829202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Own mechanical knee
Description: Daily use of own mechanical knee
Study NCT03829202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RheoKnee microprocessor prosthetic knee
Description: Daily use of RheoKnee microprocessor prosthetic knee
Study NCT01192191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg
Description: Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
Study NCT01192191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg
Description: Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
Study NCT01131832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterol
Study NCT01131832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01286480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-based Educational Intervention
Description: This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
Study NCT02973750 — intervention group
Intervention type: PROCEDURE
Intervention: Baseline Biopsy
Description: Baseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.
Study NCT02973750 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue Collection
Description: Tissue collection during debulking surgery.
Study NCT02973750 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draws
Description: Blood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.
Study NCT01587924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: tablet
Study NCT01587924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEPO
Description: injection
Study NCT00993967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone
Description: Idebenone 1350 mg/d, patients \< or equal 45 kg Idebenone 2250 mg/d, patients > 45 kg
Study NCT00460616 — intervention group
Intervention type: DRUG
Intervention: Cabergoline
Description: According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
Study NCT03399188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiome transplantation
Description: Fecal microbiota transplantation will be performed through colonoscopy to the IBD patients. Donor feces will be extensively screened for other diseases. Colonoscopy will be done at FMT center of Severance Children's Hospital twice with a month of duration. Recipients will be admitted the day before colonoscopy, and they will be discharged after a day of observation.
Study NCT02728687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Apply cream as needed up to 4 times daily to the painful foot and leg
Study NCT02728687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthol
Description: Apply cream as needed up to 4 times daily to the painful foot and leg
Study NCT02728687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol
Description: Apply cream as needed up to 4 times daily to the painful foot and leg
Study NCT01658319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT01658319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxyamine
Description: Given IV
Study NCT01658319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01658319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01658319 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies
Study NCT01658319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study NCT01658319 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Correlative studies
Study NCT01578369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise classes with pelvic floor muscle training
Description: Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
Study NCT02354053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to Triumeq
Study NCT02354053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adherence support + current ART
Study NCT02354053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence support + current ART
Study NCT00068419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study NCT00068419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Given orally
Study NCT00068419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01483261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy
Description: 15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
Study NCT03135496 — intervention group
Intervention type: OTHER
Intervention: Study of endothelial function biological markers
Description: Study of endothelial function biological markers
Study NCT01804127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
Study NCT00891943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Structured lifestyle support
Description: The intervention group will meet with a research nurse on 14 occasions over the 1 year research study, for structured lifestyle support, including dietary, physical activity and behavioral advice. They will also receive a pedometer.
Study NCT00763880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
Study NCT00763880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
Study NCT01632722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, mFOLFOX, FOLFIRI
Description: ArmA (postoperative arm)~Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2
Study NCT01632722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, mFOLFOX, FOLFIRI
Description: ArmB (perioperative arm)~Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)~Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)
Study NCT00684918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax
Description: A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
Study NCT04961684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solver Pen
Description: One application per day for 3 months
Study NCT04961684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loceryl 5%
Description: One application per week for 3 months
Study NCT03080896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet
Description: intubation using King Vision video-laryngoscope with #3 disposable blade with stylet convert to intubation with video-laryngoscope and fiber-optic bronchoscope bronchoscope (aScope III) for failure to intubate after three attempts
Study NCT03080896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope aScope III
Description: Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)
Study NCT03080896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiberoptic bronchoscope aScope III
Description: Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)
Study NCT02230033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.
Study NCT02230033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32.
Study NCT02230033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32.
Study NCT02453308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: 1. Artemether-lumefantrine for 3 days~2. Dihydroartemisinin-piperaquine for 3 days.~3. Artesunate-mefloquine for 3 days
Study NCT02453308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACT
Description: 1. Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.~2. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.~3. Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.
Study NCT02926885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL LIVER RETRACTOR DEVICE
Description: LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING CONVENTIONAL RETRACTOR DEVICE
Study NCT02926885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEXIBLE LIVER RETRACTOR DEVICE
Description: LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING FLEXIBLE LIVER RETRACTOR DEVICE
Study NCT02926885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
Description: LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
Study NCT02926885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
Description: LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
Study NCT02785523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganoderma Spore Lipids
Study NCT02785523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02785523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study NCT02785523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Study NCT00427765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test Dose = 32 mg/m\^2 IV for 1 Day; 130 mg/m\^2 IV for 4 Days
Study NCT00427765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 IV for 2 Days
Study NCT00905866 — intervention group
Intervention type: OTHER
Intervention: PAS and SF-36 questionnaires
Description: Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
Study NCT02503137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical SM04554 solution
Study NCT02503137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Vehicle solution
Study NCT02281513 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Smartphone Application
Description: Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
Study NCT02281513 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fitbit Activity Monitor
Description: Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
Study NCT02281513 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Coaching Sessions
Description: Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
Study NCT01055431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control bread
Description: Control bread
Study NCT01055431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Teff Bread
Description: Teff bread
Study NCT04257929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitolisant oral tablets
Description: Pitolisant 4.45 mg or 17.8 mg tablets
Study NCT04257929 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pitolisant oral tablets
Description: Pitolisant 4.45 mg or 17.8 mg tablets
Study NCT04257929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Matching placebo tablets
Study NCT02654769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate (Picato®)
Description: Brand product
Study NCT02654769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Ingenol Mebutate
Description: Generic formulated to have the same therapeutic effect of the brand
Study NCT02654769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
Study NCT00557713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1. -Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~2. -Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~3. -Surgery (6-8 weeks after last bevacizumab dose)~4. -Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)
Study NCT02790411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging devices
Description: technological adjustment tests
Study NCT02790411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Non Invasive Devices
Description: Tests with REX BIONICS Exoskeleton
Study NCT00737672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface
Description: Deployment of investigational stent graft at the venous anastomosis
Study NCT00737672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty
Description: Percutaneous Transluminal Angioplasty at the venous anastomosis